Contact

FOUNDATION MODELS FOR BIOMANUFACTURING

Terraferma

Terraferma builds specialized AI foundation models for protein production.

Our models and strains generalize to unseen proteins, achieving state-of-the-art titers across multiple protein classes.

Have a protein you need made? Contact us

>10B
Experimental datapoints collected
>10x
One-shot titer gains
>100x
Maximum seen titer gains

More data, better models, higher titers.

How it works

We built methods to collect the largest and cleanest datasets in the industry, powering models that design strains that work for almost any protein.
01 — Measure

Data others don’t have

Our ultra-high-throughput genetic screens collect millions to billions of reproducible datapoints per experiment. Terraferma generates and maintains one of the largest proprietary datasets linking genotype to expression phenotype.

02 — Model

Models that generalize

Trained on this data, our models predict and generate high-performing sequences that work even for proteins they’ve never seen. Our self-improving pipeline means our models become more powerful with every experiment we run.

03 — Design

Strains that work on the first try

Our model-designed strains deliver up to >10× titer gains on the first try and >100× over off-the-shelf strains, reaching double-digit titers for even difficult to produce proteins.

Case study

Ten Lives cat snacks tub
Ten Lives

Cat food economics, for any protein.

On shelves since 2024, Ten Lives features the fastest precision-fermented animal protein to reach consumers, backed by a completed safety study. Cat nutrition is one of the most cost-sensitive markets, and Terraferma’s high-titer strains enabled Ten Lives to offer sustainable animal protein at cat food prices for the first time.

Since 2026, Terraferma has expanded its platform to benefit AI protein design, food, enzyme and therapeutic partners across the protein economy.

Visit tenlives.com
For partners

Bring us a protein that’s too expensive to make.

We work with AI protein design, food, enzyme and therapeutic teams on targets that don’t express well enough to be worth making. Bring us the target; we’ll find the strain that makes it worth producing.

Start a conversation
0 → 1

Make what you couldn’t

Proteins that never expressed well enough to be worth producing. We design strains that get them to viable titers, expanding your candidate pool to proteins you’d otherwise have shelved.

1 → 100

Make what you already make, better

Already in production? We raise titers on existing targets, cutting your cost per kilogram without changing your protein.

Feasibility study

We test your protein target in our top-performing strains and report measured titers against a baseline. We can also send cell-free supernatant for your own testing.

High-throughput screening

We run custom screens for your target, using our in-house pipeline.

Licensing & co-development

License our strains, or co-develop with us and receive protein product at commercial scale.

Meet the TEAM

Our MIT and Harvard scientists, published in Nature and Molecular Cell, are based in San Francisco. Our dozens of expert partners in fermentation and biomanufacturing span across the United States.

Chief Executive Officer

Victoria Mo, MS

Victoria has over a decade of experience ranging from finetuning SOTA machine learning models to shipping both digital and physical products.

Victoria received her MS in Computer Science - Machine Learning from Columbia University.

Chief Science Officer

Dr. Ruby Yu

Ruby has spent the past decade investigating gene expression in organisms ranging from yeast to humans, and she is an industry-leading expert on high-throughput genetic screens for machine learning.

She received both her BA and her PhD in Biological and Biomedical Sciences from Harvard University, and completed her postdoc at Gladstone Institutes and UCSF (Marson Lab).

VP of Science

Dr. Emma Kowal

Emma has over a decade of experience in molecular and computational biology. She specializes in high-throughput assays measuring gene expression, end-to-end from library design through sequencing data analysis.

She received her PhD in Biology from MIT (Burge Lab) and BA in Chemical and Physical Biology from Harvard University (Church Lab).

Advisors
Dr. Doug Cameron
Cargill · Khosla Ventures
Dr. Audrey Diano
ADM · Novozymes
Dr. Glenn Nedwin
Novozymes
Dr. Ben Erichson
UC Berkeley · AI Genesis
Dr. Kelly Swanson
UIUC · Nutrition
Warren Rickard
Zoetis · Pet health

Proud Recipient of the NSF SBIR

View More

Accelerating Innovation with the NSF Convergence Grant

View More

Joining Y Combinator

View More

Our backers